Peer-influenced content. Sources you trust. No registration required. This is HCN.
This feature article from the BMJ discusses how and why American oncologists are rushing to prioritize the patients at greatest risk, institute new protections, and learn from their collective experiences during the COVID-19 pandemic.
Family Medicine/General Practice May 4th 2020
Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.
Allergy & Immunology April 27th 2020
The Journal of Internal Medicine stresses that, although the timing of antiviral therapy may significantly slow COVID-19 progression, the study was underpowered to evaluate the therapeutic effect of the drugs and they should continue to be used only in studies, not empirical use.
JAMA Network
A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.
Although timely access to the results of studies evaluating patients with cancer infected with COVID-19 is urgently needed, such evidence is currently very limited. The CCC19 hopes to change all of that.
Allergy & Immunology April 20th 2020
Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.